Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference - Yahoo Finance
| 0A9G Stock | 3.90 0.04 1.04% |
Slightly above 51% of Mereo BioPharma's investor base is interested to short. The analysis of overall sentiment of trading Mereo BioPharma Group stock suggests that many investors are impartial at this time. Mereo BioPharma's investing sentiment can be driven by a variety of factors including economic data, Mereo BioPharma's earnings reports, geopolitical events, and overall market trends.
Mereo BioPharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Mereo daily returns and investor perception about the current price of Mereo BioPharma Group as well as its diversification or hedging effects on your existing portfolios.
Mereo |
Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference Yahoo Finance
Read at news.google.com
 |
Mereo BioPharma Fundamental Analysis
We analyze Mereo BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Mereo BioPharma is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Mereo BioPharma Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mereo BioPharma stock to make a market-neutral strategy. Peer analysis of Mereo BioPharma could also be used in its relative valuation, which is a method of valuing Mereo BioPharma by comparing valuation metrics with similar companies.
Peers
Mereo BioPharma Related Equities
| SMSD | Samsung Electronics | 3.83 | ||||
| SMSN | Samsung Electronics | 2.98 | ||||
| HYUD | Hyundai | 2.67 | ||||
| 0QYR | Panasonic Corp | 1.41 | ||||
| 0RUK | MOL Hungarian | 0.00 | ||||
| RIGD | Reliance Industries | 0.66 | ||||
| HSBK | Halyk Bank | 2.57 |
Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.